Modification of the tumor microenvironment to enhance immunity

Frontiers in Bioscience

Volumn 12, Issue 10, 2007, Pages 3576-3600

  Liao, Yu Pei ^a   Schaue, Dorthe ^a   McBride, William H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Immune cells; Immune system; Immunity; Microenvironment; Neoplasia; Review; Tumor

Indexed keywords

ANIMAL; HUMAN; IMMUNOLOGY; NEOPLASM; REGULATORY T LYMPHOCYTE; REVIEW; VASCULARIZATION;

ANIMALS; HUMANS; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 34347221896     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2336     Document Type: Article

References (346)

1. Balkwill, F. & A. Mantovani: Inflammation and cancer: back to Virchow? Lancet, 357, 539-545 (2001) (Pubitemid 32173595)
2. Ehrlich, P.: Uber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd., 5, 273-290 (1909)
3. Burnet, M.: Cancer; a biological approach. I. The processes of control. Br Med J 779-86 (1957)
4. Thomas, L.: In: Cellular and Humoral Aspects of the Hypersensitive States Ed: H. S. Lawrence. P. B Hoeber, New York (1959)
5. Thor Straten, P., P. Guldberg, K. Gronbak, M. R. Hansen, A. F. Kirkin, T. Seremet, J. Zeuthen & J. C. Becker: In situ T Cell Responses Against Melanoma Comprise High Numbers of Locally Expanded T Cell Clonotypes. J Immunol, 163, 443-447 (1999) (Pubitemid 29295872)
6. Rosenberg, S. A.: Progress in the development of immunotherapy for the treatment of patients with cancer. Journal of Internal Medicine, 250, 462-475 (2001) (Pubitemid 34013510)
7. Bremers, A. J. A. & G. Parmiani: Immunology and immunotherapy of human cancer: present concepts and clinical developments. Critical Reviews in Oncology/Hematology, 34, 1-25 (2000) (Pubitemid 30227314)
8. Boon, T., P. G. Coulie & B. Van den Eynde: Tumor antigens recognized by T cells. Immunol Today, 18, 267-8 (1997) (Pubitemid 27261443)
9. Matzinger, P.: The danger model: a renewed sense of self. Science, 296, 301-305 (2002) (Pubitemid 34303674)
10. Fuchs, E. J. & P. Matzinger: Is cancer dangerous to the immune system? Semin. Immunol., 8, 271-280 (1996) (Pubitemid 26413867)
11. Gajewski, T. F., Y. Meng & H. Harlin: Immune suppression in the tumor microenvironment. J Immunother, 29, 233-40 (2006) (Pubitemid 44297291)
12. Gray, L. H., A. D. Conger, M. Ebert, S. Hornsey & O. C. Scott: The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol, 26, 638-48 (1953)
13. Haghnegahdar, H., J. Du, D. Wang, R. M. Strieter, M. D. Burdick, L. B. Nanney, N. Cardwell, J. Luan, R. Shattuck-Brandt & A. Richmond: The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol, 67, 53-62 (2000) (Pubitemid 30046818)
14. Mrowietz, U., U. Schwenk, S. Maune, J. Bartels, M. Kupper, I. Fichtner, J. M. Schroder & D. Schadendorf: The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer, 79, 1025-31 (1999) (Pubitemid 29087870)
15. Loukinova, E., G. Dong, I. Enamorado-Ayalya, G. R. Thomas, Z. Chen, H. Schreiber & C. Van Waes: Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene, 19, 3477-86 (2000) (Pubitemid 30487445)
16. Soler, D., T. L. Humphreys, S. M. Spinola & J. J. Campbell: CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood, 101, 1677-82 (2003)
17. Kurt, R. A., A. Baher, K. P. Wisner, S. Tackitt & W. J. Urba: Chemokine receptor desensitization in tumor-bearing mice. Cell Immunol, 207, 81-8 (2001) (Pubitemid 32225449)
18. Peng, L., S. Shu & J. C. Krauss: Monocyte chemoattractant protein inhibits the generation of tumorreactive T cells. Cancer Res, 57, 4849-54 (1997) (Pubitemid 27468993)
19. Van Den Hove, L. E., S. W. Van Gool, H. Van Poppel, L. Baert, L. Coorevits, B. Van Damme & J. L. Ceuppens: Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol, 109, 501-9 (1997) (Pubitemid 27402320)
20. Hellstrom, I., J. A. Ledbetter, N. Scholler, Y. Yang, Z. Ye, G. Goodman, J. Pullman, M. Hayden-Ledbetter & K. E. Hellstrom: CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proc Natl Acad Sci U S A, 98, 6783-8 (2001) (Pubitemid 32538294)
21. Guilloux, Y., C. Viret, N. Gervois, E. Le Drean, M. C. Pandolfino, E. Diez & F. Jotereau: Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur J Immunol, 24, 1966-73 (1994)
22. Roussel, E., M. C. Gingras, E. A. Grimm & J. A. Roth: High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumorinfiltrating lymphocytes from lung adenocarcinoma. Cancer Immunol Immunother, 41, 1-9 (1995)
23. Radoja, S., M. Saio, D. Schaer, M. Koneru, S. Vukmanovic & A. B. Frey: CD8 (+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J Immunol, 167, 5042-51 (2001) (Pubitemid 33009737)
24. Mortarini, R., A. Piris, A. Maurichi, A. Molla, I. Bersani, A. Bono, C. Bartoli, M. Santinami, C. Lombardo, F. Ravagnani, N. Cascinelli, G. Parmiani & A. Anichini: Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to selfantigens in human metastatic melanoma. Cancer Res, 63, 2535-45 (2003) (Pubitemid 36605194)
25. Zippelius, A., P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, N. Rufer, N. Lubenow, D. Speiser, J. C. Cerottini, P. Romero & M. J. Pittet: Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res, 64, 2865-73 (2004) (Pubitemid 38500627)
26. Nakagomi, H., P. Pisa, E. K. Pisa, Y. Yamamoto, E. Halapi, K. Backlin, C. Juhlin & R. Kiessling: Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer, 63, 366-71 (1995)
27. Roussel, E., M. C. Gingras, E. A. Grimm, J. M. Bruner & R. P. Moser: Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol, 105, 344-52 (1996) (Pubitemid 26246956)
28. Whiteside, T. L. & G. Parmiani: Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother, 39, 15-21 (1994) (Pubitemid 24216607)
29. Vose, B. M. & M. Moore: Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol, 22, 27-40 (1985)
30. Mizoguchi, H., J. O'Shea, D. Longo, C. Loeffler, D. McVicar & A. Ochoa: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice 10.1126/science.1465616. Science, 258, 1795-1798 (1992) (Pubitemid 23087347)
31. Kuss, I., T. Saito, J. T. Johnson & T. L. Whiteside: Clinical Significance of Decreased zeta Chain Expression in Peripheral Blood Lymphocytes of Patients with Head and Neck Cancer. Clin Cancer Res, 5, 329-334 (1999) (Pubitemid 29085186)
32. Lai, P., H. Rabinowich, P. A. Crowley-Nowick, M. C. Bell, G. Mantovani & T. L. Whiteside: Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res, 2, 161-73 (1996) (Pubitemid 26042190)
33. Healy, C. G., J. W. Simons, M. A. Carducci, T. L. DeWeese, M. Bartkowski, K. P. Tong & W. E. Bolton: Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry, 32, 109-19 (1998) (Pubitemid 28246758)
34. Riccobon, A., R. Gunelli, R. Ridolfi, F. De Paola, E. Flamini, M. Fiori, C. Saltutti, M. Petrini, L. Fiammenghi, M. Stefanelli, A. M. Granato, D. E. Cuzzocrea & D. Amadori: Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumorinfiltrating, near-tumor tissue, and peripheral blood lymphocytes. Cancer Invest, 22, 871-7 (2004) (Pubitemid 39665352)
35. Koneru, M., D. Schaer, N. Monu, A. Ayala & A. B. Frey: Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function. J Immunol, 174, 1830-40 (2005) (Pubitemid 40223922)
36. Chen, X., A. Woiciechowsky, S. Raffegerst, D. Schendel, H.-J. Kolb & M. Roskrow: Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis doi:10.1046/j.1365-2141.2000.02415.x. British Journal of Haematology, 111, 817-825 (2000) (Pubitemid 32098920)
37. Dworacki, G., N. Meidenbauer, I. Kuss, T. K. Hoffmann, W. Gooding, M. Lotze & T. L. Whiteside: Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res, 7, 947s-957s (2001) (Pubitemid 33600950)
38. Reichert, T. E., H. Rabinowich, J. T. Johnson & T. L. Whiteside: Mechanisms responsible for signaling and functional defects. J Immunother, 21, 295-306 (1998) (Pubitemid 28328409)
39. Bauernhofer, T., I. Kuss, B. Henderson, A. S. Baum & T. L. Whiteside: Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol, 33, 119-24 (2003) (Pubitemid 36157649)
40. Whiteside, T. L.: Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol, 12, 43-50 (2002) (Pubitemid 34087897)
41. Whiteside, T. L.: Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother, 53, 865-78 (2004) (Pubitemid 39312654)
42. Zea, A. H., P. C. Rodriguez, K. S. Culotta, C. P. Hernandez, J. DeSalvo, J. B. Ochoa, H. J. Park, J. Zabaleta & A. C. Ochoa: L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol, 232, 21-31 (2004) (Pubitemid 40732717)
43. Loeffler, D. A., P. L. Juneau & S. Masserant: Influence of tumour physico-chemical conditions on interleukin-2-stimulated lymphocyte proliferation. Br J Cancer, 66, 619-22 (1992)
44. Masson, D., P. J. Peters, H. J. Geuze, J. Borst & J. Tschopp: Interaction of chondroitin sulfate with perforin and granzymes of cytolytic T-cells is dependent on pH. Biochemistry, 29, 11229-35 (1990)
45. Severin, T., B. Muller, G. Giese, B. Uhl, B. Wolf, S. Hauschildt & W. Kreutz: pH-dependent LAK cell cytotoxicity. Tumour Biol, 15, 304-10 (1994) (Pubitemid 24360700)
46. Loeffler, D. A., P. L. Juneau & G. H. Heppner: Natural killer-cell activity under conditions reflective of tumor micro-environment. Int J Cancer, 48, 895-9 (1991)
47. Radosevic, K., B. G. de Grooth & J. Greve: Changes in intracellular calcium concentration and pH of target cells during the cytotoxic process: a quantitative study at the single cell level. Cytometry, 20, 281-9 (1995)
48. Le, Q. T., G. Shi, H. Cao, D. W. Nelson, Y. Wang, E. Y. Chen, S. Zhao, C. Kong, D. Richardson, K. J. O'Byrne, A. J. Giaccia & A. C. Koong: Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol, 23, 8932-41 (2005) (Pubitemid 46211478)
49. Caldwell, C. C., H. Kojima, D. Lukashev, J. Armstrong, M. Farber, S. G. Apasov & M. V. Sitkovsky: Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol, 167, 6140-9 (2001) (Pubitemid 33081540)
50. Berendt, M. J. & R. J. North: T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med, 151, 69-80 (1980) (Pubitemid 10168540)
51. Roncarolo, M. G. & M. K. Levings: The role of different subsets of T regulatory cells in controlling autoimmunity. Curr Opin Immunol, 12, 676-83 (2000)
52. Bach, J. F.: Regulatory T cells under scrutiny. Nat Rev Immunol, 3, 189-98 (2003) (Pubitemid 37323204)
53. Sutmuller, R. P., L. M. van Duivenvoorde, A. van Elsas, T. N. Schumacher, M. E. Wildenberg, J. P. Allison, R. E. Toes, R. Offringa & C. J. Melief: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25 (+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med, 194, 823-32 (2001) (Pubitemid 32983017)
54. Tanaka, H., J. Tanaka, J. Kjaergaard & S. Shu: Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother, 25, 207-17 (2002) (Pubitemid 34533310)
55. Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure & D. C. Linehan: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol, 169, 2756-61 (2002) (Pubitemid 34921025)
56. Woo, E. Y., C. S. Chu, T. J. Goletz, K. Schlienger, H. Yeh, G. Coukos, S. C. Rubin, L. R. Kaiser & C. H. June: Regulatory CD4 (+) CD25 (+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res, 61, 4766-72 (2001) (Pubitemid 32691889)
57. Woo, E. Y., H. Yeh, C. S. Chu, K. Schlienger, R. G. Carroll, J. L. Riley, L. R. Kaiser & C. H. June: Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation. J Immunol, 168, 4272-4276 (2002) (Pubitemid 34441324)
58. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M. L. Disis, K. L. Knutson, L. Chen & W. Zou: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 10, 942-9 (2004) (Pubitemid 39273735)
59. Viguier, M., F. Lemaitre, O. Verola, M. S. Cho, G. Gorochov, L. Dubertret, H. Bachelez, P. Kourilsky & L. Ferradini: Foxp3 expressing CD4+CD25 (high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol, 173, 1444-53 (2004) (Pubitemid 38924326)
60. Ghiringhelli, F., P. E. Puig, S. Roux, A. Parcellier, E. Schmitt, E. Solary, G. Kroemer, F. Martin, B. Chauffert & L. Zitvogel: Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med, 202, 919-29 (2005) (Pubitemid 41396892)
61. June, C. H., J. A. Bluestone, L. M. Nadler & C. B. Thompson: The B7 and CD28 receptor families. Immunol Today, 15, 321-31 (1994) (Pubitemid 24231747)
62. Dong, H., G. Zhu, K. Tamada & L. Chen: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Med., 5, 1365-1369 (1999)
63. Curiel, T. J.: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Med., 9, 562-567 (2003) (Pubitemid 36597102)
64. Chen, L.: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol, 4, 336-47 (2004) (Pubitemid 38649276)
65. Zou, W.: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer, 5, 263-74 (2005) (Pubitemid 40488632)
66. Vermi, W., R. Bonecchi, F. Facchetti, D. Bianchi, S. Sozzani, S. Festa, A. Berenzi, M. Cella & M. Colonna: Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol, 200, 255-68 (2003) (Pubitemid 36748035)
67. Preynat-Seauve, O., P. Schuler, E. Contassot, F. Beermann, B. Huard & L. E. French: Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J Immunol, 176, 61-7 (2006) (Pubitemid 43023249)
68. Vicari, A. P., I. Treilleux & S. Lebecque: Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin Cancer Biol, 14, 161-9 (2004) (Pubitemid 38586741)
69. Zou, W., V. Machelon, A. Coulomb-L'Hermin, J. Borvak, F. Nome, T. Isaeva, S. Wei, R. Krzysiek, I. Durand-Gasselin, A. Gordon, T. Pustilnik, D. T. Curiel, P. Galanaud, F. Capron, D. Emilie & T. J. Curiel: Stromalderived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med, 7, 1339-46 (2001) (Pubitemid 34007939)
70. Salio, M.: Plasmacytoid dendritic cells prime IFN-[gamma]-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur. J. Immunol., 33, 1052-1062 (2003) (Pubitemid 36546693)
71. Scarpino, S., A. Stoppacciaro, F. Ballerini, M. Marchesi, M. Prat, M. C. Stella, S. Sozzani, P. Allavena, A. Mantovani & L. P. Ruco: Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol, 156, 831-7 (2000) (Pubitemid 30626941)
72. Negus, R. P., G. W. Stamp, J. Hadley & F. R. Balkwill: Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol, 150, 1723-34 (1997) (Pubitemid 27193819)
73. Tang, K. F., S. Y. Tan, S. H. Chan, S. M. Chong, K. S. Loh, L. K. Tan & H. Hu: A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: implication for the intense tumor infiltration by T lymphocytes and macrophages. Hum Pathol, 32, 42-9 (2001) (Pubitemid 32150627)
74. Tan, J. K. & H. C. O'Neill: Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity. J Leukoc Biol, 78, 319-24 (2005) (Pubitemid 41061304)
75. Bell, D., P. Chomarat, D. Broyles, G. Netto, G. M. Harb, S. Lebecque, J. Valladeau, J. Davoust, K. A. Palucka & J. Banchereau: In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med, 190, 1417-26 (1999)
76. Iwamoto, M., H. Shinohara, A. Miyamoto, M. Okuzawa, H. Mabuchi, T. Nohara, G. Gon, M. Toyoda & N. Tanigawa: Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer, 104, 92-7 (2003) (Pubitemid 36184151)
77. Troy, A., P. Davidson, C. Atkinson & D. Hart: Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol, 160, 214-9 (1998) (Pubitemid 29479465)
78. Troy, A. J., K. L. Summers, P. J. Davidson, C. H. Atkinson & D. N. Hart: Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res, 4, 585-93 (1998) (Pubitemid 28193556)
79. Kalinski, P., J. H. Schuitemaker, C. M. Hilkens & M. L. Kapsenberg: Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol., 161, 2804-2809 (1998) (Pubitemid 28425700)
80. Sombroek, C. C.: Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol., 168, 4333-4343 (2002) (Pubitemid 34441333)
81. Akasaki, Y.: Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J. Immunol., 173, 4352-4359 (2004) (Pubitemid 39280663)
82. Menetrier-Caux, C.: Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood, 92, 4778-4791 (1998) (Pubitemid 29005881)
83. Munn, D. H., M. D. Sharma, J. R. Lee, K. G. Jhaver, T. S. Johnson, D. B. Keskin, B. Marshall, P. Chandler, S. J. Antonia, R. Burgess, C. L. Slingluff, Jr. & A. L. Mellor: Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase. Science, 297, 1867-70 (2002) (Pubitemid 35024345)
84. Dougherty, G. J. & W. H. McBride: Immunoregulating activity of tumor-associated macrophages. Cancer Immunol Immunother, 23, 67-72 (1986) (Pubitemid 16018452)
85. Dougherty, G. J. & W. H. McBride: Accessory cell activity of murine tumor-associated macrophages. J Natl Cancer Inst, 76, 541-8 (1986) (Pubitemid 16119791)
86. Curiel, T. J., P. Cheng, P. Mottram, X. Alvarez, L. Moons, M. Evdemon-Hogan, S. Wei, L. Zou, I. Kryczek, G. Hoyle, A. Lackner, P. Carmeliet & W. Zou: Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res, 64, 5535-8 (2004) (Pubitemid 39095544)
87. Conejo-Garcia, J. R., F. Benencia, M. C. Courreges, E. Kang, A. Mohamed-Hadley, R. J. Buckanovich, D. O. Holtz, A. Jenkins, H. Na, L. Zhang, D. S. Wagner, D. Katsaros, R. Caroll & G. Coukos: Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med, 10, 950-8 (2004) (Pubitemid 39273736)
88. Gilliet, M. & Y. J. Liu: Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med., 195, 695-704 (2002) (Pubitemid 34259715)
89. Rissoan, M. C., V. Soumelis, N. Kadowaki, G. Grouard, F. Briere, R. de Waal Malefyt & Y. J. Liu: Reciprocal control of T helper cell and dendritic cell differentiation. Science, 283, 1183-6 (1999)
90. van Ravenswaay Claasen, H. H., P. M. Kluin & G. J. Fleuren: Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest, 67, 166-74 (1992)
91. Toomey, D., J. Harmey, C. Condron, E. Kay & D. Bouchier-Hayes: Phenotyping of immune cell infiltrates in breast and colorectal tumours. Immunol Invest, 28, 29-41 (1999) (Pubitemid 29072821)
92. Leek, R. D.: The prognostic role of angiogenesis in breast cancer. Anticancer Res, 21, 4325-31 (2001) (Pubitemid 34240962)
93. Hashimoto, I., J. Kodama, N. Seki, A. Hongo, Y. Miyagi, M. Yoshinouchi & T. Kudo: Macrophage infiltration and angiogenesis in endometrial cancer. Anticancer Res, 20, 4853-6 (2000) (Pubitemid 32127741)
94. Leek, R. D., R. J. Landers, A. L. Harris & C. E. Lewis: Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer, 79, 991-5 (1999) (Pubitemid 29082138)
95. McBride, W. H.: Phenotype and functions of intratumoral macrophages. Biochim Biophys Acta, 865, 27-41 (1986) (Pubitemid 16050201)
96. Moore, K. & W. H. McBride: Enhanced Fc receptor expression by a sub-population of murine intra-tumour macrophages following intravenous Corynebacterium parvum therapy. Br J Cancer, 47, 797-802 (1983) (Pubitemid 13053509)
97. Mantovani, A.: Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Invest, 71, 5-16 (1994) (Pubitemid 24246016)
98. Burke, B., N. Tang, K. P. Corke, D. Tazzyman, K. Ameri, M. Wells & C. E. Lewis: Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol, 196, 204-12 (2002) (Pubitemid 34110902)
99. Lewis, C. E. & J. W. Pollard: Distinct role of macrophages in different tumor microenvironments. Cancer Res, 66, 605-12 (2006) (Pubitemid 43165918)
100. Condeelis, J. & J. W. Pollard: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell, 124, 263-6 (2006) (Pubitemid 43121975)
101. Elgert, K. D., D. G. Alleva & D. W. Mullins: Tumorinduced immune dysfunction: the macrophage connection. J. Leukoc. Biol., 64, 275-290 (1998) (Pubitemid 28409233)
102. Harmey, J. H., E. Dimitriadis, E. Kay, H. P. Redmond & D. Bouchier-Hayes: Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol, 5, 271-8 (1998) (Pubitemid 28249320)
103. Alleva, D. G., C. J. Burger & K. D. Elgert: Tumorinduced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol, 153, 1674-86 (1994) (Pubitemid 24251112)
104. Aso, H., K. Tamura, O. Yoshie, T. Nakamura, S. Kikuchi & N. Ishida: Impaired NK response of cancer patients to IFN-alpha but not to IL-2: correlation with serum immunosuppressive acidic protein (IAP) and role of suppressor macrophage. Microbiol Immunol, 36, 1087-97 (1992) (Pubitemid 23000642)
105. Naama, H. A., V. E. Mack, G. P. Smyth, P. P. Stapleton & J. M. Daly: Macrophage effector mechanisms in melanoma in an experimental study. Arch Surg, 136, 804-9 (2001) (Pubitemid 32642802)
106. al-Sarireh, B. & O. Eremin: Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. J R Coll Surg Edinb, 45, 1-16 (2000) (Pubitemid 35385843)
107. Park, Y. M., R. L. Anderson, D. R. Spitz & G. M. Hahn: Hypoxia and resistance to hydrogen peroxide confer resistance to tumor necrosis factor in murine L929 cells. Radiat Res, 131, 162-8 (1992)
108. Naldini, A., S. Cesari & V. Bocci: Effects of hypoxia on the cytotoxicity mediated by tumor necrosis factoralpha. Lymphokine Cytokine Res, 13, 233-7 (1994) (Pubitemid 24280941)
109. Lynch, E. M., L. E. Sampson, A. A. Khalil, M. R. Horsman & D. J. Chaplin: Cytotoxic effect of tumour necrosis factor-alpha on sarcoma F cells at tumour relevant oxygen tensions. Acta Oncol, 34, 423-7 (1995)
110. Park, S. Y., H. Lee, J. Hur, S. Y. Kim, H. Kim, J. H. Park, S. Cha, S. S. Kang, G. J. Cho, W. S. Choi & K. Suk: Hypoxia induces nitric oxide production in mouse microglia via p38 mitogen-activated protein kinase pathway. Brain Res Mol Brain Res, 107, 9-16 (2002) (Pubitemid 35333200)
111. Lee, V. Y., D. S. McClintock, M. T. Santore, G. R. Budinger & N. S. Chandel: Hypoxia sensitizes cells to nitric oxide-induced apoptosis. J Biol Chem, 277, 16067-74 (2002) (Pubitemid 34967891)
112. Zhao, H., N. Dugas, C. Mathiot, A. Delmer, B. Dugas, F. Sigaux & J. P. Kolb: B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood, 92, 1031-43 (1998) (Pubitemid 28355488)
113. Mannick, J. B., X. Q. Miao & J. S. Stamler: Nitric oxide inhibits Fas-induced apoptosis. J Biol Chem, 272, 24125-8 (1997) (Pubitemid 27418605)
114. Hegardt, P., B. Widegren & H. O. Sjogren: Nitricoxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas. Cell Immunol, 200, 116-27 (2000) (Pubitemid 30228261)
115. Polverini, P. J. & S. J. Leibovich: Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest, 51, 635-42 (1984) (Pubitemid 15182529)
116. Fukumura, D. & R. K. Jain: Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev, 17, 77-89 (1998) (Pubitemid 28194647)
117. Fukumura, D., S. Kashiwagi & R. K. Jain: The role of nitric oxide in tumour progression. Nat Rev Cancer, 6, 521-34 (2006) (Pubitemid 43980541)
118. Chang, C. I., J. C. Liao & L. Kuo: Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res, 61, 1100-6 (2001) (Pubitemid 32174431)
119. Stout, R. D., C. Jiang, B. Matta, I. Tietzel, S. K. Watkins & J. Suttles: Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol, 175, 342-9 (2005) (Pubitemid 40884337)
120. Ben-Baruch, A.: Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumormicroenvironment interactions. Breast Cancer Res, 5, 31-6 (2003) (Pubitemid 36553576)
121. Miles, D. W., L. C. Happerfield, M. S. Naylor, L. G. Bobrow, R. D. Rubens & F. R. Balkwill: Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer, 56, 777-82 (1994) (Pubitemid 24102739)
122. Leek, R. D., R. Landers, S. B. Fox, F. Ng, A. L. Harris & C. E. Lewis: Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer, 77, 2246-51 (1998) (Pubitemid 28263948)
123. Balkwill, F.: Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev, 13, 135-41 (2002) (Pubitemid 34229388)
124. Partridge, M., D. Chantry, M. Turner & M. Feldmann: Production of interleukin-1 and interleukin-6 by human keratinocytes and squamous cell carcinoma cell lines. J Invest Dermatol, 96, 771-6 (1991)
125. Mann, E. A., J. D. Spiro, L. L. Chen & D. L. Kreutzer: Cytokine expression by head and neck squamous cell carcinomas. Am J Surg, 164, 567-73 (1992)
126. Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin & R. L. Coffman: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol, 136, 2348-57 (1986) (Pubitemid 16136806)
127. Wittke, F., R. Hoffmann, J. Buer, I. Dallmann, K. Oevermann, S. Sel, T. Wandert, A. Ganser & J. Atzpodien: Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer, 79, 1182-4 (1999) (Pubitemid 29087895)
128. Shim, K. S., K. H. Kim, W. S. Han & E. B. Park: Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer, 85, 554-61 (1999) (Pubitemid 29075277)
129. Bohlen, H., M. Kessler, M. Sextro, V. Diehl & H. Tesch: Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol, 79, 110-3 (2000) (Pubitemid 30195606)
130. Villanueva, A., C. Garcia, A. B. Paules, M. Vicente, M. Megias, G. Reyes, P. de Villalonga, N. Agell, F. Lluis, O. Bachs & G. Capella: Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene, 17, 1969-78 (1998) (Pubitemid 28488465)
131. Jong, H. S., H. S. Lee, T. Y. Kim, Y. H. Im, J. W. Park, N. K. Kim & Y. J. Bang: Attenuation of transforming growth factor beta-induced growth inhibition in human hepatocellular carcinoma cell lines by cyclin D1 overexpression. Biochem Biophys Res Commun, 292, 383-9 (2002) (Pubitemid 34694275)
132. Peng, Y., Y. Laouar, M. O. Li, E. A. Green & R. A. Flavell: TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A, 101, 4572-7 (2004) (Pubitemid 38437452)
133. Steinbrink, K., H. Jonuleit, G. Muller, G. Schuler, J. Knop & A. H. Enk: Interleukin-10-treated human dendritic cells induce a melanoma-antigen- specific anergy in CD8 (+) T cells resulting in a failure to lyse tumor cells. Blood, 93, 1634-42 (1999) (Pubitemid 29102491)
134. Qin, Z., G. Noffz, M. Mohaupt & T. Blankenstein: Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colonystimulating factor gene-modified tumor cells. J Immunol, 159, 770-6 (1997) (Pubitemid 127484228)
135. Wolff, H.: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res., 58, 4997-5001 (1998) (Pubitemid 28521147)
136. Shono, T., P. J. Tofilon, J. M. Bruner, O. Owolabi & F. F. Lang: Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res., 61, 4375-4381 (2001) (Pubitemid 32685762)
137. Joki, T.: Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res., 60, 4926-4931 (2000)
138. Sanchez-Elsner, T., J. R. Ramirez, F. Rodriguez-Sanz, E. Varela, C. Bernabeu & L. M. Botella: A Cross-Talk Between Hypoxia and TGF-[beta] Orchestrates Erythropoietin Gene Regulation Through SP1 and Smads. Journal of Molecular Biology, 336, 9-24 (2004) (Pubitemid 38102327)
139. Dynlacht, J. R., M. Earles, J. Henthorn, Z. V. Roberts, E. W. Howard, J. D. Seno, D. Sparling & M. D. Story: Degradation of the nuclear matrix is a common element during radiation-induced apoptosis and necrosis. Radiat Res, 152, 590-603 (1999)
140. Rainaldi, G., A. Ferrante, P. L. Indovina & M. T. Santini: Induction of apoptosis or necrosis by ionizing radiation is dose-dependent in MG-63 osteosarcoma multicellular spheroids. Anticancer Res, 23, 2505-18 (2003) (Pubitemid 36897121)
141. Larmonier, N., D. Merino, A. Nicolas, D. Cathelin, A. Besson, A. Bateman, E. Solary, F. Martin, E. Katsanis & B. Bonnotte: Apoptotic, necrotic, or fused tumor cells: An equivalent source of antigen for dendritic cell loading. Apoptosis (2006)
142. Dillman, R., N. Barth, L. Vandermolen, K. Mahdavi, L. Beutel, C. de Leon, C. DePriest & S. Nayak: Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm, 19, 570-80 (2004) (Pubitemid 39546296)
143. Galili, U.: Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer. Cancer Immunol Immunother, 53, 935-45 (2004) (Pubitemid 39371738)
144. Galetto, A., S. Buttiglieri, S. Forno, F. Moro, A. Mussa & L. Matera: Drug-and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs, 14, 833-43 (2003) (Pubitemid 38339789)
145. Santin, A. D., J. C. Hiserodt, J. Fruehauf, P. J. DiSaia, S. Pecorelli & G. A. Granger: Effects of irradiation on the expression of surface antigens in human ovarian cancer. Gynecol Oncol, 60, 468-74 (1996) (Pubitemid 26077638)
146. Morel, A., N. Fernandez, A. de La Coste, H. Haddada, M. Viguier, B. S. Polla, B. Antoine & A. Kahn: Gamma-ray irradiation induces B7.1 costimulatory molecule neoexpression in various murine tumor cells. Cancer Immunol Immunother, 46, 277-82 (1998)
147. Seo, A., F. Ishikawa, H. Nakano, H. Nakazaki, K. Kobayashi & T. Kakiuchi: Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation. Immunology, 96, 642-8 (1999) (Pubitemid 29179805)
148. Chakraborty, M., S. I. Abrams, K. Camphausen, K. Liu, T. Scott, C. N. Coleman & J. W. Hodge: Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol, 170, 6338-47 (2003) (Pubitemid 36682620)
149. Garnett, C. T., C. Palena, M. Chakraborty, K. Y. Tsang, J. Schlom & J. W. Hodge: Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res, 64, 7985-94 (2004) (Pubitemid 39446933)
150. Reits, E. A., J. W. Hodge, C. A. Herberts, T. A. Groothuis, M. Chakraborty, E. K. Wansley, K. Camphausen, R. M. Luiten, A. H. de Ru, J. Neijssen, A. Griekspoor, E. Mesman, F. A. Verreck, H. Spits, J. Schlom, P. van Veelen & J. J. Neefjes: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med, 203, 1259-71 (2006) (Pubitemid 43736595)
151. Newcomb, E. W., S. Demaria, Y. Lukyanov, Y. Shao, T. Schnee, N. Kawashima, L. Lan, J. K. Dewyngaert, D. Zagzag, W. H. McBride & S. C. Formenti: The combination of ionizing radiation and peripheral vaccination produces longterm survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res, 12, 4730-7 (2006) (Pubitemid 44297827)
152. Lugade, A. A., J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger & E. M. Lord: Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigenspecific effector cells that traffic to the tumor. J Immunol, 174, 7516-23 (2005) (Pubitemid 40806254)
153. McBride, W. H.: Cytokine cascades in late normal tissue radiation responses. Int J Radiat Oncol Biol Phys, 33, 233-4 (1995)
154. Hong, J. H., C. S. Chiang, I. L. Campbell, J. R. Sun, H. R. Withers & W. H. McBride: Induction of acute phase gene expression by brain irradiation. Int J Radiat Oncol Biol Phys, 33, 619-26 (1995)
155. Hong, J. H., C. S. Chiang, C. Y. Tsao, P. Y. Lin, W. H. McBride & C. J. Wu: Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol, 75, 1421-7 (1999)
156. Rube, C. E., H. P. Rodemann & C. Rube: [The relevance of cytokines in the radiation-induced lung reaction. Experimental basis and clinical significance]. Strahlenther Onkol, 180, 541-9 (2004) (Pubitemid 39248786)
157. Anscher, M. S., I. R. Crocker & R. L. Jirtle: Transforming growth factor-beta 1 expression in irradiated liver. Radiat Res, 122, 77-85 (1990) (Pubitemid 20130056)
158. Barcellos-Hoff, M. H., R. Derynck, M. L. Tsang & J. A. Weatherbee: Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest, 93, 892-9 (1994)
159. Ruifrok, A. C., K. A. Mason, G. Lozano & H. D. Thames: Spatial and temporal patterns of expression of epidermal growth factor, transforming growth factor alpha and transforming growth factor beta 1-3 and their receptors in mouse jejunum after radiation treatment. Radiat Res, 147, 1-12 (1997) (Pubitemid 27014441)
160. McBride, W. H., C. S. Chiang, J. L. Olson, C. C. Wang, J. H. Hong, F. Pajonk, G. J. Dougherty, K. S. Iwamoto, M. Pervan & Y. P. Liao: A sense of danger from radiation. Radiat Res, 162, 1-19 (2004) (Pubitemid 39044714)
161. Lumniczky, K., S. Desaknai, L. Mangel, B. Szende, H. Hamada, E. J. Hidvegi & G. Safrany: Local tumor irradiation augments the antitumor effect of cytokineproducing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther, 9, 44-52 (2002) (Pubitemid 34052853)
162. Teitz-Tennenbaum, S., Q. Li, S. Rynkiewicz, F. Ito, M. A. Davis, C. J. McGinn & A. E. Chang: Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res, 63, 8466-75 (2003) (Pubitemid 37549503)
163. Chakraborty, M., S. I. Abrams, C. N. Coleman, K. Camphausen, J. Schlom & J. W. Hodge: External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res, 64, 4328-37 (2004) (Pubitemid 38802440)
164. Kudo-Saito, C., J. Schlom, K. Camphausen, C. N. Coleman & J. W. Hodge: The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res, 11, 4533-44 (2005) (Pubitemid 40825644)
165. Hewitt, H. B., E. Blake & E. H. Proter: The effect of lethally irradiated cells on the transplantability of murine tumours. Br J Cancer, 28, 123-35 (1973)
166. Hewitt, H. B. & E. R. Blake: Failure of preoperative C. parvum vaccine to modify secondary disease following excision of two non-immunogenic murine carcinomas. Br J Cancer, 38, 219-23 (1978) (Pubitemid 9007109)
167. Tsai, C. H., J. H. Hong, K. F. Hsieh, H. W. Hsiao, W. L. Chuang, C. C. Lee, W. H. McBride & C. S. Chiang: Tetracycline-regulated intratumoral expression of interleukin-3 enhances the efficacy of radiation therapy for murine prostate cancer. Cancer Gene Ther (2006)
168. Wenger, F. A., C. A. Jacobi, J. Zieren, W. Docke, H. D. Volk & J. M. Muller: Tumor size and lymph-node status in pancreatic carcinoma - is there a correlation to the preoperative immune function? Langenbecks Arch Surg, 384, 473-8 (1999) (Pubitemid 29513736)
169. Hallahan, D., J. Kuchibhotla & C. Wyble: Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res, 56, 5150-5 (1996) (Pubitemid 26383029)
170. Quarmby, S., R. D. Hunter & S. Kumar: Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells. Anticancer Res, 20, 3375-81 (2000)
171. Heckmann, M., K. Douwes, R. Peter & K. Degitz: Vascular activation of adhesion molecule mRNA and cell surface expression by ionizing radiation. Exp Cell Res, 238, 148-54 (1998) (Pubitemid 28366137)
172. Onoda, J. M., S. S. Kantak, M. P. Piechocki & C. A. Diglio: Low dose radiation induces endothelial cell eicosanoid metabolism and cytoskeletal rearrangement. Adv Exp Med Biol, 400 B, 879-87 (1997)
173. Prabhakarpandian, B., D. J. Goetz, R. A. Swerlick, X. Chen & M. F. Kiani: Expression and functional significance of adhesion molecules on cultured endothelial cells in response to ionizing radiation. Microcirculation, 8, 355-64 (2001) (Pubitemid 33598139)
174. Mao, X. W.: A quantitative study of the effects of ionizing radiation on endothelial cells and capillary-like network formation. Technol Cancer Res Treat, 5, 127-34 (2006)
175. Tsai, J. H., S. Makonnen, M. Feldman, C. M. Sehgal, A. Maity & W. M. Lee: Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis. Cancer Biol Ther, 4, 1395-1400 (2005) (Pubitemid 43131187)
176. Garcia-Barros, M., F. Paris, C. Cordon-Cardo, D. Lyden, S. Rafii, A. Haimovitz-Friedman, Z. Fuks & R. Kolesnick: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science, 300, 1155-9 (2003) (Pubitemid 36583102)
177. Kalofonos, H., G. Rowlinson & A. A. Epenetos: Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation. Cancer Res, 50, 159-63 (1990) (Pubitemid 20030011)
178. Barcellos-Hoff, M. H.: Radiation-induced transforming growth factor beta and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res, 53, 3880-6 (1993) (Pubitemid 23267682)
179. Znati, C. A., M. Rosenstein, Y. Boucher, M. W. Epperly, W. D. Bloomer & R. K. Jain: Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res, 56, 964-68 (1996) (Pubitemid 26065386)
180. Znati, C. A., M. Rosenstein, T. D. McKee, E. Brown, D. Turner, W. D. Bloomer, S. Watkins, R. K. Jain & Y. Boucher: Irradiation reduces interstitial fluid transport and increases the collagen content in tumors. Clin Cancer Res, 9, 5508-13 (2003) (Pubitemid 37499469)
181. Crokart, N., B. F. Jordan, C. Baudelet, R. Ansiaux, P. Sonveaux, V. Gregoire, N. Beghein, J. DeWever, C. Bouzin, O. Feron & B. Gallez: Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int J Radiat Oncol Biol Phys, 63, 901-10 (2005) (Pubitemid 41400082)
182. Tsai, C. H., F. H. Chen, C. C. Wang, H. L. Huang, S. M. Jung, C. J. Wu, C. C. Lee, W. H. McBride, C. S. Chiang & J. H. Hong: Macrophages from irradiated tumors express higher levels of iNOS, Arginase-I, and promote tumor growth (submitted)
183. Mantovani, A., A. Sica, S. Sozzani, P. Allavena, A. Vecchi & M. Locati: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol, 25, 677-86 (2004) (Pubitemid 39457982)
184. Philippe, J., H. Louagie, H. Thierens, A. Vral, M. Cornelissen & L. De Ridder: Quantification of apoptosis in lymphocyte subsets and effect of apoptosis on apparent expression of membrane antigens. Cytometry, 29, 242-9 (1997) (Pubitemid 27501795)
185. Belka, C., H. Ottinger, E. Kreuzfelder, M. Weinmann, M. Lindemann, A. Lepple-Wienhues, W. Budach, H. Grosse-Wilde & M. Bamberg: Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother Oncol, 50, 199-204 (1999) (Pubitemid 29155546)
186. North, R. J.: Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J Exp Med, 164, 1652-66 (1986) (Pubitemid 17184195)
187. Awwad, M. & R. J. North: Sublethal, whole-body ionizing irradiation can be tumor promotive or tumor destructive depending on the stage of development of underlying antitumor immunity. Cancer Immunol Immunother, 26, 55-60 (1988) (Pubitemid 18048427)
188. Hellstrom, K. E., I. Hellstrom, J. A. Kant & J. D. Tamerius: Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. J Exp Med, 148, 799-804 (1978) (Pubitemid 9006461)
189. Tilkin, A. F., N. Schaaf-Lafontaine, A. Van Acker, M. Boccadoro & J. Urbain: Reduced tumor growth after lowdose irradiation or immunization against blastic suppressor T cells. Proc Natl Acad Sci U S A, 78, 1809-12 (1981) (Pubitemid 11114266)
190. Yu, P., Y. Lee, W. Liu, T. Krausz, A. Chong, H. Schreiber & Y. X. Fu: Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med, 201, 779-91 (2005) (Pubitemid 40395122)
191. Liao, Y. P., C. C. Wang, L. H. Butterfield, J. S. Economou, A. Ribas, W. S. Meng, K. S. Iwamoto & W. H. McBride: Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol, 173, 2462-9 (2004) (Pubitemid 39063103)
192. Chen, Z., D. Xia, X. Bi, A. Saxena, N. Sidhu, A. El-Gayed & J. Xiang: Combined radiation therapy and dendritic cell vaccine for treating solid tumors with liver micro-metastasis. J Gene Med (2004)
193. Younes, E., G. P. Haas, B. Dezso, E. Ali, R. L. Maughan, M. A. Kukuruga, E. Montecillo, J. E. Pontes & G. G. Hillman: Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol, 165, 243-51 (1995)
194. Nishisaka, N., R. F. Jones, P. Morse, K. Kuratsukuri, R. Romanowski, C. Y. Wang & G. P. Haas: Inhibition of lung metastases of murine renal cell carcinoma by the combination of radiation and interferon-alpha-producing tumor cell vaccine. Cytokines Cell Mol Ther, 6, 199-206 (2000)
195. Lee, J., J. P. Moran, B. M. Fenton, C. J. Koch, J. G. Frelinger, P. C. Keng & E. M. Lord: Alteration of tumour response to radiation by interleukin-2 gene transfer. Br J Cancer, 82, 937-44 (2000) (Pubitemid 30085249)
196. McBride, W. H., G. D. Dougherty, A. E. Wallis, J. S. Economou & C. S. Chiang: Interleukin-3 in gene therapy of cancer. Folia Biol (Praha), 40, 62-73 (1994) (Pubitemid 24218739)
197. Chiang, C. S., J. H. Hong, Y. C. Wu, W. H. McBride & G. J. Dougherty: Combining radiation therapy with interleukin-3 gene immunotherapy. Cancer Gene Ther, 7, 1172-8 (2000) (Pubitemid 30661035)
198. Chiang, C. S., R. G. Syljuasen, J. H. Hong, A. Wallis, G. J. Dougherty & W. H. McBride: Effects of IL-3 gene expression on tumor response to irradiation in vitro and in vivo. Cancer Res, 57, 3899-903 (1997) (Pubitemid 27427672)
199. Gulley, J. L., P. M. Arlen, A. Bastian, S. Morin, J. Marte, P. Beetham, K. Y. Tsang, J. Yokokawa, J. W. Hodge, C. Menard, K. Camphausen, C. N. Coleman, F. Sullivan, S. M. Steinberg, J. Schlom & W. Dahut: Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res, 11, 3353-62 (2005) (Pubitemid 40627887)
200. Lake, R. A. & B. W. Robinson: Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer, 5, 397-405 (2005) (Pubitemid 40637831)
201. Emens, L. A. & E. M. Jaffee: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res, 65, 8059-64 (2005) (Pubitemid 41330564)
202. van der Most, R. G., A. Currie, B. W. Robinson & R. A. Lake: Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen crosspresentation towards useful antitumor immunity. Cancer Res, 66, 601-4 (2006) (Pubitemid 43165917)
203. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, L. J. Rogers, G. J. Gracia, S. A. Jones, D. P. Mangiameli, M. M. Pelletier, J. Gea-Banacloche, M. R. Robinson, D. M. Berman, A. C. Filie, A. Abati & S. A. Rosenberg: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 23, 2346-57 (2005) (Pubitemid 46218728)
204. Polak, L. & J. L. Turk: Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature, 249, 654-6 (1974)
205. North, R. J.: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med, 155, 1063-74 (1982) (Pubitemid 12142723)
206. Hoover, S. K., S. K. Barrett, T. M. Turk, T. C. Lee & H. D. Bear: Cyclophosphamide and abrogation of tumorinduced suppressor T cell activity. Cancer Immunol Immunother, 31, 121-7 (1990) (Pubitemid 20113441)
207. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte & F. Martin: CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol, 34, 336-44 (2004) (Pubitemid 39255944)
208. Berd, D. & M. J. Mastrangelo: Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res, 48, 1671-5 (1988) (Pubitemid 18091225)
209. Schiavoni, G., F. Mattei, T. Di Pucchio, S. M. Santini, L. Bracci, F. Belardelli & E. Proietti: Cyclophosphamide induces type I interferon and augments the number of CD44 (hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood, 95, 2024-30 (2000) (Pubitemid 30151641)
210. Loeffler, M., J. A. Kruger & R. A. Reisfeld: Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res, 65, 5027-30 (2005) (Pubitemid 40827309)
211. Proietti, E., G. Greco, B. Garrone, S. Baccarini, C. Mauri, M. Venditti, D. Carlei & F. Belardelli: Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest, 101, 429-41 (1998) (Pubitemid 28067341)
212. Nowak, A. K., B. W. Robinson & R. A. Lake: Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemoimmunotherapy. Cancer Res, 62, 2353-8 (2002) (Pubitemid 34411717)
213. Suzuki, E., V. Kapoor, A. S. Jassar, L. R. Kaiser & S. M. Albelda: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res, 11, 6713-21 (2005) (Pubitemid 41339014)
214. Nowak, A. K., B. W. Robinson & R. A. Lake: Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res, 63, 4490-6 (2003) (Pubitemid 36951021)
215. Ben-Hur, H., G. Kossoy, J. Zandbank & I. Zusman: Response of the immune system of mammary tumorbearing rats to cyclophosphamide and soluble lowmolecular-mass tumor-associated antigens: rate of lymphoid infiltration and distribution of T lymphocytes in tumors. Int J Mol Med, 9, 425-30 (2002)
216. Nakashima, H., A. Tasaki, M. Kubo, H. Kuroki, K. Matsumoto, M. Tanaka, M. Nakamura, T. Morisaki & M. Katano: Effects of docetaxel on antigen presentationrelated functions of human monocyte-derived dendritic cells. Cancer Chemother Pharmacol, 55, 479-87 (2005) (Pubitemid 40568979)
217. Browder, T., C. E. Butterfield, B. M. Kraling, B. Shi, B. Marshall, M. S. O'Reilly & J. Folkman: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res, 60, 1878-86 (2000) (Pubitemid 30207647)
218. Bocci, G., K. C. Nicolaou & R. S. Kerbel: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res, 62, 6938-43 (2002) (Pubitemid 35424084)
219. Drevs, J., J. Fakler, S. Eisele, M. Medinger, G. Bing, N. Esser, D. Marme & C. Unger: Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res, 24, 1759-63 (2004) (Pubitemid 38954706)
220. Jassar, A. S., E. Suzuki, V. Kapoor, J. Sun, M. B. Silverberg, L. Cheung, M. D. Burdick, R. M. Strieter, L. M. Ching, L. R. Kaiser & S. M. Albelda: Activation of tumor-associated macrophages by the vascular disrupting agent 5, 6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res, 65, 11752-61 (2005) (Pubitemid 41821737)
221. Heath, W. R., G. T. Belz, G. M. Behrens, C. M. Smith, S. P. Forehan, I. A. Parish, G. M. Davey, N. S. Wilson, F. R. Carbone & J. A. Villadangos: Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev, 199, 9-26 (2004) (Pubitemid 38736761)
222. Nowak, A. K., R. A. Lake, A. L. Marzo, B. Scott, W. R. Heath, E. J. Collins, J. A. Frelinger & B. W. Robinson: Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than crosstolerizing host tumor-specific CD8 T cells. J Immunol, 170, 4905-13 (2003) (Pubitemid 36554719)
223. Mullins, D. W., C. J. Burger & K. D. Elgert: Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol, 162, 6811-8 (1999) (Pubitemid 29309409)
224. Byrd-Leifer, C. A., E. F. Block, K. Takeda, S. Akira & A. Ding: The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol, 31, 2448-57 (2001) (Pubitemid 32785364)
225. Joo, H. G.: Altered maturation of dendritic cells by taxol, an anticancer drug. J Vet Sci, 4, 229-34 (2003)
226. Coral, S., L. Sigalotti, M. Altomonte, A. Engelsberg, F. Colizzi, I. Cattarossi, E. Maraskovsky, E. Jager, B. Seliger & M. Maio: 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res, 8, 2690-5 (2002) (Pubitemid 34856358)
227. Ohtsukasa, S., S. Okabe, H. Yamashita, T. Iwai & K. Sugihara: Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. J Cancer Res Clin Oncol, 129, 719-26 (2003) (Pubitemid 38002303)
228. AbdAlla, E. E., G. E. Blair, R. A. Jones, H. M. Sue-Ling & D. Johnston: Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. J Natl Cancer Inst, 87, 489-96 (1995)
229. Rad, A. N., G. Pollara, S. M. Sohaib, C. Chiang, B. M. Chain & D. R. Katz: The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation. Cancer Res, 63, 5143-50 (2003) (Pubitemid 37022656)
230. Vereecque, R., A. Saudemont & B. Quesnel: Cytosine arabinoside induces co-stimulatory molecule expression in acute myeloid leukemia cells. Leukemia, 18, 1223-30 (2004) (Pubitemid 39023132)
231. Do, Y., V. L. Hegde, P. S. Nagarkatti & M. Nagarkatti: Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells. Cancer Res, 64, 6756-65 (2004) (Pubitemid 39297939)
232. Bergmann-Leitner, E. S. & S. I. Abrams: Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother, 50, 445-55 (2001) (Pubitemid 33079340)
233. Correale, P., M. T. Del Vecchio, G. Di Genova, G. G. Savellini, M. La Placa, C. Terrosi, M. Vestri, R. Urso, F. Lemonnier, A. Aquino, E. Bonmassar, G. Giorgi, G. Francini & M. G. Cusi: 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthasedirected polyepitopic peptide vaccine. J Natl Cancer Inst, 97, 1437-45 (2005) (Pubitemid 41520079)
234. Yang, S. & F. G. Haluska: Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzymeand Fas-mediated pathways. J Immunol, 172, 4599-608 (2004) (Pubitemid 38375278)
235. Frost, P. J., L. H. Butterfield, V. B. Dissette, J. S. Economou & B. Bonavida: Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures. J Immunol, 166, 3564-73 (2001) (Pubitemid 33117362)
236. Machiels, J. P., R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye & E. M. Jaffee: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factorsecreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res, 61, 3689-97 (2001) (Pubitemid 32694981)
237. Pressley, J. S. & K. D. Elgert: Post-chemotherapeutic administration of interleukin-12 retards tumor growth and enhances immune cell function: combination therapy using paclitaxel and IL-12. Cancer Invest, 24, 351-9 (2006)
238. Allendorf, J. D., M. Bessler, R. L. Whelan, M. Trokel, D. A. Laird, M. B. Terry & M. R. Treat: Postoperative immune function varies inversely with the degree of surgical trauma in a murine model. Surg Endosc, 11, 427-30 (1997) (Pubitemid 127523826)
239. Ordemann, J., C. A. Jacobi, W. Schwenk, R. Stosslein & J. M. Muller: Cellular and humoral inflammatory response after laparoscopic and conventional colorectal resections. Surg Endosc, 15, 600-8 (2001) (Pubitemid 32500130)
240. Whelan, R. L., M. Franklin, S. D. Holubar, J. Donahue, R. Fowler, C. Munger, J. Doorman, J. E. Balli, J. Glass, J. J. Gonzalez, M. Bessler, H. Xie & M. Treat: Postoperative cell mediated immune response is better preserved after laparoscopic vs open colorectal resection in humans. Surg Endosc, 17, 972-8 (2003) (Pubitemid 36676913)
241. Bolla, G. & G. Tuzzato: Immunologic postoperative competence after laparoscopy versus laparotomy. Surg Endosc, 17, 1247-50 (2003) (Pubitemid 37064801)
242. Leung, K. L., K. S. Tsang, M. H. Ng, K. J. Leung, P. B. Lai, J. F. Lee & W. Y. Lau: Lymphocyte subsets and natural killer cell cytotoxicity after laparoscopically assisted resection of rectosigmoid carcinoma. Surg Endosc, 17, 1305-10 (2003) (Pubitemid 37064813)
243. Wichmann, M. W., T. P. Huttl, H. Winter, F. Spelsberg, M. K. Angele, M. M. Heiss & K. W. Jauch: Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study. Arch Surg, 140, 692-7 (2005) (Pubitemid 41124008)
244. Whelan, R. L.: Laparotomy, laparoscopy, cancer, and beyond. Surg Endosc, 15, 110-5 (2001) (Pubitemid 32274447)
245. Wouters, B. G., M. Koritzinsky, R. K. Chiu, J. Theys, J. Buijsen & P. Lambin: Modulation of cell death in the tumor microenvironment. Semin Radiat Oncol, 13, 31-41 (2003) (Pubitemid 36173258)
246. Crokart, N., K. Radermacher, B. F. Jordan, C. Baudelet, G. O. Cron, V. Gregoire, N. Beghein, C. Bouzin, O. Feron & B. Gallez: Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect. Cancer Res, 65, 7911-6 (2005) (Pubitemid 41297269)
247. Hur, E., H. H. Kim, S. M. Choi, J. H. Kim, S. Yim, H. J. Kwon, Y. Choi, D. K. Kim, M. O. Lee & H. Park: Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol, 62, 975-82 (2002) (Pubitemid 35222488)
248. Mabjeesh, N. J., D. Escuin, T. M. LaVallee, V. S. Pribluda, G. M. Swartz, M. S. Johnson, M. T. Willard, H. Zhong, J. W. Simons & P. Giannakakou: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell, 3, 363-75 (2003) (Pubitemid 38340305)
249. Fang, J., Z. Cao, Y. C. Chen, E. Reed & B. H. Jiang: 9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells. Mol Pharmacol, 66, 178-86 (2004) (Pubitemid 38822101)
250. Isaacs, J. S., Y. J. Jung, E. G. Mimnaugh, A. Martinez, F. Cuttitta & L. M. Neckers: Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alphadegradative pathway. J Biol Chem, 277, 29936-44 (2002)
251. Jones, M. K., I. L. Szabo, H. Kawanaka, S. S. Husain & A. S. Tarnawski: von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. Faseb J, 16, 264-6 (2002)
252. Rapisarda, A., R. H. Shoemaker & G. Melillo: Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle, 3, 172-5 (2004) (Pubitemid 40268692)
253. Liu, X. H., A. Kirschenbaum, M. Lu, S. Yao, A. Dosoretz, J. F. Holland & A. C. Levine: Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem, 277, 50081-6 (2002) (Pubitemid 36014461)
254. Rapisarda, A., B. Uranchimeg, D. A. Scudiero, M. Selby, E. A. Sausville, R. H. Shoemaker & G. Melillo: Identification of small molecule inhibitors of hypoxiainducible factor 1 transcriptional activation pathway. Cancer Res, 62, 4316-24 (2002) (Pubitemid 34827288)
255. Chau, N. M., P. Rogers, W. Aherne, V. Carroll, I. Collins, E. McDonald, P. Workman & M. Ashcroft: Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Res, 65, 4918-28 (2005) (Pubitemid 40740832)
256. Tan, C., R. G. de Noronha, A. J. Roecker, B. Pyrzynska, F. Khwaja, Z. Zhang, H. Zhang, Q. Teng, A. C. Nicholson, P. Giannakakou, W. Zhou, J. J. Olson, M. M. Pereira, K. C. Nicolaou & E. G. Van Meir: Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res, 65, 605-12 (2005)
257. Kong, D., E. J. Park, A. G. Stephen, M. Calvani, J. H. Cardellina, A. Monks, R. J. Fisher, R. H. Shoemaker & G. Melillo: Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res, 65, 9047-55 (2005) (Pubitemid 41377397)
258. Kurabayashi, A., M. Furihata, M. Matsumoto, H. Hayashi & Y. Ohtsuki: Distribution of tumor-infiltrating dendritic cells in human non-small cell lung carcinoma in relation to apoptosis. Pathol Int, 54, 302-10 (2004) (Pubitemid 38716491)
259. Gan, Y., J. L. Au, J. Lu & M. G. Wientjes: Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures. Pharm Res, 15, 1760-6 (1998) (Pubitemid 28524589)
260. Lin, S., S. C. Tsai, C. C. Lee, B. W. Wang, J. Y. Liou & K. G. Shyu: Berberine inhibits HIF-1alpha expression via enhanced proteolysis. Mol Pharmacol, 66, 612-9 (2004) (Pubitemid 39329260)
261. Kojima, H., H. Gu, S. Nomura, C. C. Caldwell, T. Kobata, P. Carmeliet, G. L. Semenza & M. V. Sitkovsky: Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha-deficient chimeric mice. Proc Natl Acad Sci U S A, 99, 2170-4 (2002) (Pubitemid 34169033)
262. Kojima, H., M. V. Sitkovsky & M. Cascalho: HIF-1 alpha deficiency perturbs T and B cell functions. Curr Pharm Des, 9, 1827-32 (2003) (Pubitemid 37010086)
263. Makino, Y., H. Nakamura, E. Ikeda, K. Ohnuma, K. Yamauchi, Y. Yabe, L. Poellinger, Y. Okada, C. Morimoto & H. Tanaka: Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J Immunol, 171, 6534-40 (2003) (Pubitemid 37532083)
264. Oda, T., K. Hirota, K. Nishi, S. Takabuchi, S. Oda, H. Yamada, T. Arai, K. Fukuda, T. Kita, T. Adachi, G. L. Semenza & R. Nohara: Activation of hypoxia-inducible factor 1 during macrophage differentiation. Am J Physiol Cell Physiol, 291, C104-13 (2006)
265. Hopfl, G., O. Ogunshola & M. Gassmann: HIFs and tumors-causes and consequences. Am J Physiol Regul Integr Comp Physiol, 286, R608-23 (2004)
266. Hellwig-Burgel, T., D. P. Stiehl, A. E. Wagner, E. Metzen & W. Jelkmann: Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon Cytokine Res, 25, 297-310 (2005) (Pubitemid 40911381)
267. Cramer, T., Y. Yamanishi, B. E. Clausen, I. Forster, R. Pawlinski, N. Mackman, V. H. Haase, R. Jaenisch, M. Corr, V. Nizet, G. S. Firestein, H. P. Gerber, N. Ferrara & R. S. Johnson: HIF-1alpha is essential for myeloid cellmediated inflammation. Cell, 112, 645-57 (2003) (Pubitemid 36331777)
268. Albina, J. E., B. Mastrofrancesco, J. A. Vessella, C. A. Louis, W. L. Henry, Jr. & J. S. Reichner: HIF-1 expression in healing wounds: HIF-1alpha induction in primary inflammatory cells by TNF-alpha. Am J Physiol Cell Physiol, 281, C1971-7 (2001)
269. Sun, X., J. R. Kanwar, E. Leung, K. Lehnert, D. Wang & G. W. Krissansen: Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther, 8, 638-45 (2001) (Pubitemid 32422058)
270. Lewis, C. & C. Murdoch: Macrophage responses to hypoxia: implications for tumor progression and anticancer therapies. Am J Pathol, 167, 627-35 (2005) (Pubitemid 41216349)
271. Peyssonnaux, C., V. Datta, T. Cramer, A. Doedens, E. A. Theodorakis, R. L. Gallo, N. Hurtado-Ziola, V. Nizet & R. S. Johnson: HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest, 115, 1806-15 (2005) (Pubitemid 40979719)
272. Lahat, N., M. A. Rahat, M. Ballan, L. Weiss-Cerem, M. Engelmayer & H. Bitterman: Hypoxia reduces CD80 expression on monocytes but enhances their LPS-stimulated TNF-alpha secretion. J Leukoc Biol, 74, 197-205 (2003) (Pubitemid 38040416)
273. Bosco, M. C., M. Puppo, S. Pastorino, Z. Mi, G. Melillo, S. Massazza, A. Rapisarda & L. Varesio: Hypoxia selectively inhibits monocyte chemoattractant protein-1 production by macrophages. J Immunol, 172, 1681-90 (2004) (Pubitemid 38116816)
274. Rahat, M. A., B. Marom, H. Bitterman, L. Weiss-Cerem, A. Kinarty & N. Lahat: Hypoxia reduces the output of matrix metalloproteinase-9 (MMP-9) in monocytes by inhibiting its secretion and elevating membranal association. J Leukoc Biol, 79, 706-18 (2006) (Pubitemid 44835603)
275. Schlichting, C. L., W. D. Schareck & M. Weis: Renal ischemia-reperfusion injury: new implications of dendritic cell-endothelial cell interactions. Transplant Proc, 38, 670-3 (2006)
276. Meehan, R., U. Duncan, L. Neale, G. Taylor, H. Muchmore, N. Scott, K. Ramsey, E. Smith, P. Rock, R. Goldblum & et al.: Operation Everest II: alterations in the immune system at high altitudes. J Clin Immunol, 8, 397-406 (1988)
277. Maurus, C. F., M. K. Schneider, D. Schmidt, G. Zund & J. D. Seebach: Activation of human microvascular endothelial cells with TNF-alpha and hypoxia/reoxygenation enhances NK-cell adhesion, but not NK-Cytotoxicity. Transplantation, 81, 1204-11 (2006)
278. Helmlinger, G., F. Yuan, M. Dellian & R. K. Jain: Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med, 3, 177-82 (1997) (Pubitemid 27064702)
279. Fukumura, D., L. Xu, Y. Chen, T. Gohongi, B. Seed & R. K. Jain: Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res, 61, 6020-4 (2001) (Pubitemid 32762531)
280. Mekhail, K., M. Khacho, L. Gunaratnam & S. Lee: Oxygen sensing by H+: implications for HIF and hypoxic cell memory. Cell Cycle, 3, 1027-9 (2004) (Pubitemid 40268659)
281. Cecchi, A., A. Hulikova, J. Pastorek, S. Pastorekova, A. Scozzafava, J. Y. Winum, J. L. Montero & C. T. Supuran: Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem, 48, 4834-41 (2005) (Pubitemid 41033126)
282. Cairns, R., I. Papandreou & N. Denko: Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res, 4, 61-70 (2006)
283. Lardner, A.: The effects of extracellular pH on immune function. J Leukoc Biol, 69, 522-30 (2001) (Pubitemid 32294836)
284. Heming, T. A., S. K. Dave, D. M. Tuazon, A. K. Chopra, J. W. Peterson & A. Bidani: Effects of extracellular pH on tumour necrosis factor-alpha production by resident alveolar macrophages. Clin Sci (Lond), 101, 267-74 (2001) (Pubitemid 32835524)
285. Harhaji, L., D. Popadic, D. Miljkovic, I. Cvetkovic, A. Isakovic & V. Trajkovic: Acidosis affects tumor cell survival through modulation of nitric oxide release. Free Radic Biol Med, 40, 226-35 (2006) (Pubitemid 43069348)
286. Fischer, B., B. Muller, P. Fisch & W. Kreutz: An acidic microenvironment inhibits antitumoral non-major histocompatibility complex-restricted cytotoxicity: implications for cancer immunotherapy. J Immunother, 23, 196-207 (2000) (Pubitemid 30165169)
287. Vermeulen, M., M. Giordano, A. S. Trevani, C. Sedlik, R. Gamberale, P. Fernandez-Calotti, G. Salamone, S. Raiden, J. Sanjurjo & J. R. Geffner: Acidosis improves uptake of antigens and MHC class I-restricted presentation by dendritic cells. J Immunol, 172, 3196-204 (2004) (Pubitemid 38263711)
288. Joyce, J. A.: Therapeutic targeting of the tumor microenvironment. Cancer Cell, 7, 513-20 (2005) (Pubitemid 40799245)
289. Jain, R. K.: Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol, 29, 3-9 (2002)
290. Willett, C. G., Y. Boucher, E. di Tomaso, D. G. Duda, L. L. Munn, R. T. Tong, D. C. Chung, D. V. Sahani, S. P. Kalva, S. V. Kozin, M. Mino, K. S. Cohen, D. T. Scadden, A. C. Hartford, A. J. Fischman, J. W. Clark, D. P. Ryan, A. X. Zhu, L. S. Blaszkowsky, H. X. Chen, P. C. Shellito, G. Y. Lauwers & R. K. Jain: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10, 145-7 (2004) (Pubitemid 38524883)
291. Jain, R. K.: Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med, 7, 987-9 (2001) (Pubitemid 32937367)
292. Sun, X., J. R. Kanwar, E. Leung, K. Lehnert, D. Wang & G. W. Krissansen: Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Ther, 8, 719-27 (2001) (Pubitemid 32983128)
293. Clauss, M., M. Gerlach, H. Gerlach, J. Brett, F. Wang, P. C. Familletti, Y. C. Pan, J. V. Olander, D. T. Connolly & D. Stern: Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med, 172, 1535-45 (1990)
294. Ramanathan, M., A. Giladi & S. J. Leibovich: Regulation of vascular endothelial growth factor gene expression in murine macrophages by nitric oxide and hypoxia. Exp Biol Med (Maywood), 228, 697-705 (2003) (Pubitemid 37163260)
295. Leek, R. D., N. C. Hunt, R. J. Landers, C. E. Lewis, J. A. Royds & A. L. Harris: Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol, 190, 430-6 (2000) (Pubitemid 30163582)
296. Leek, R. D., C. E. Lewis, R. Whitehouse, M. Greenall, J. Clarke & A. L. Harris: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res, 56, 4625-9 (1996) (Pubitemid 26338061)
297. Tsutsui, S., K. Yasuda, K. Suzuki, K. Tahara, H. Higashi & S. Era: Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep, 14, 425-31 (2005)
298. Kaplan, R. N., R. D. Riba, S. Zacharoulis, A. H. Bramley, L. Vincent, C. Costa, D. D. MacDonald, D. K. Jin, K. Shido, S. A. Kerns, Z. Zhu, D. Hicklin, Y. Wu, J. L. Port, N. Altorki, E. R. Port, D. Ruggero, S. V. Shmelkov, K. K. Jensen, S. Rafii & D. Lyden: VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature, 438, 820-7 (2005) (Pubitemid 41753060)
299. Rafii, S.: Vaccination against tumor neovascularization: Promise and reality. Cancer Cell, 2, 429-31 (2002) (Pubitemid 41043945)
300. Li, Y., M. N. Wang, H. Li, K. D. King, R. Bassi, H. Sun, A. Santiago, A. T. Hooper, P. Bohlen & D. J. Hicklin: Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med, 195, 1575-84 (2002) (Pubitemid 34666071)
301. Dong, Y., J. Qian, R. Ibrahim, J. A. Berzofsky & S. N. Khleif: Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J Immunother, 29, 32-40 (2006)
302. Zhou, H., Y. Luo, M. Mizutani, N. Mizutani, R. A. Reisfeld & R. Xiang: T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood, 106, 2026-32 (2005) (Pubitemid 41291716)
303. Niethammer, A. G., R. Xiang, J. C. Becker, H. Wodrich, U. Pertl, G. Karsten, B. P. Eliceiri & R. A. Reisfeld: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med, 8, 1369-75 (2002) (Pubitemid 36019421)
304. Wada, S., T. Tsunoda, T. Baba, F. J. Primus, H. Kuwano, M. Shibuya & H. Tahara: Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res, 65, 4939-46 (2005) (Pubitemid 40740834)
305. Nair, S., D. Boczkowski, B. Moeller, M. Dewhirst, J. Vieweg & E. Gilboa: Synergy between tumor immunotherapy and antiangiogenic therapy. Blood, 102, 964-71 (2003) (Pubitemid 36917791)
306. Coussens, L. M., B. Fingleton & L. M. Matrisian: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 295, 2387-92 (2002) (Pubitemid 34270240)
307. Overall, C. M. & O. Kleifeld: Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer, 6, 227-39 (2006) (Pubitemid 43292566)
308. Parks, W. C., C. L. Wilson & Y. S. Lopez-Boado: Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol, 4, 617-29 (2004) (Pubitemid 39025047)
309. McQuibban, G. A., J. H. Gong, J. P. Wong, J. L. Wallace, I. Clark-Lewis & C. M. Overall: Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood, 100, 1160-7 (2002) (Pubitemid 34864266)
310. Baratelli, F. E., N. Heuze-Vourc'h, K. Krysan, M. Dohadwala, K. Riedl, S. Sharma & S. M. Dubinett: Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix. J Immunol, 173, 5458-66 (2004) (Pubitemid 39392130)
311. Mantena, S. K., A. M. Roy & S. K. Katiyar: Epigallocatechin-3-gallate inhibits photocarcinogenesis through inhibition of angiogenic factors and activation of CD8+ T cells in tumors. Photochem Photobiol, 81, 1174-9 (2005) (Pubitemid 41545942)
312. Sheu, B. C., S. M. Hsu, H. N. Ho, H. C. Lien, S. C. Huang & R. H. Lin: A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res, 61, 237-42 (2001)
313. Davis, G. E., K. J. Bayless, M. J. Davis & G. A. Meininger: Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am J Pathol, 156, 1489-98 (2000) (Pubitemid 30646688)
314. Schenk, S. & V. Quaranta: Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol, 13, 366-75 (2003) (Pubitemid 36776714)
315. Jin, H. & J. Varner: Integrins: roles in cancer development and as treatment targets. Br J Cancer, 90, 561-5 (2004) (Pubitemid 38297190)
316. Rosenberg, S. A.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med., 4, 321-327 (1998) (Pubitemid 28144091)
317. Johnson, T. W., K. E. Anderson, D. Lazovich & A. R. Folsom: Association of aspirin and nonsteroidal antiinflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev, 11, 1586-91 (2002) (Pubitemid 36020011)
318. Pollard, M. & P. H. Luckert: Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Lett, 25, 117-21 (1984) (Pubitemid 15195072)
319. Thun, M. J., M. M. Namboodiri, E. E. Calle, W. D. Flanders & C. W. Heath, Jr.: Aspirin use and risk of fatal cancer. Cancer Res, 53, 1322-7 (1993) (Pubitemid 23097110)
320. Jacobs, E. J., C. J. Connell, C. Rodriguez, A. V. Patel, E. E. Calle & M. J. Thun: Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst, 96, 524-8 (2004) (Pubitemid 38559576)
321. Jacobs, E. J., C. Rodriguez, A. M. Mondul, C. J. Connell, S. J. Henley, E. E. Calle & M. J. Thun: A large cohort study of aspirin and other nonsteroidal antiinflammatory drugs and prostate cancer incidence. J Natl Cancer Inst, 97, 975-80 (2005) (Pubitemid 41430563)
322. Lee, J., B. M. Fenton, C. J. Koch, J. G. Frelinger & E. M. Lord: Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res, 58, 1478-85 (1998) (Pubitemid 28193611)
323. Bonvalot, S., A. Laplanche, F. Lejeune, E. Stoeckle, C. Le Pechoux, D. Vanel, P. Terrier, J. Lumbroso, M. Ricard, G. Antoni, A. Cavalcanti, C. Robert, N. Lassau, J. Y. Blay & A. Le Cesne: Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol, 16, 1061-8 (2005) (Pubitemid 41418306)
324. Grunhagen, D. J., J. H. de Wilt, W. J. Graveland, C. Verhoef, A. N. van Geel & A. M. Eggermont: Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer, 106, 1776-84 (2006)
325. Stolina, M., S. Sharma, Y. Lin, M. Dohadwala, B. Gardner, J. Luo, L. Zhu, M. Kronenberg, P. W. Miller, J. Portanova, J. C. Lee & S. M. Dubinett: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol, 164, 361-70 (2000) (Pubitemid 30013010)
326. Sharma, S., M. Stolina, S. C. Yang, F. Baratelli, J. F. Lin, K. Atianzar, J. Luo, L. Zhu, Y. Lin, M. Huang, M. Dohadwala, R. K. Batra & S. M. Dubinett: Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res, 9, 961-8 (2003) (Pubitemid 36323698)
327. Hahn, T., I. Alvarez, J. J. Kobie, L. Ramanathapuram, S. Dial, A. Fulton, D. Besselsen, E. Walker & E. T. Akporiaye: Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int J Cancer, 118, 2220-31 (2006)
328. Kundu, N., T. C. Walser, X. Ma & A. M. Fulton: Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother, 54, 981-7 (2005) (Pubitemid 41187706)
329. Haas, A. R., J. Sun, A. Vachani, A. F. Wallace, M. Silverberg, V. Kapoor & S. M. Albelda: Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res, 12, 214-22 (2006) (Pubitemid 43166197)
330. Basu, G. D., T. L. Tinder, J. M. Bradley, T. Tu, C. L. Hattrup, B. A. Pockaj & P. Mukherjee: Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO. J Immunol, 177, 2391-402 (2006) (Pubitemid 44201000)
331. Karin, M.: NF-kappaB and cancer: mechanisms and targets. Mol Carcinog, 45, 355-61 (2006)
332. Karin, M., Y. Yamamoto & Q. M. Wang: The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov, 3, 17-26 (2004) (Pubitemid 38088695)
333. Luo, J. L., S. Maeda, L. C. Hsu, H. Yagita & M. Karin: Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell, 6, 297-305 (2004) (Pubitemid 39222042)
334. Hodge, J. W., S. Abrams, J. Schlom & J. A. Kantor: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 co-stimulatory molecules. Cancer Res, 54, 5552-5 (1994) (Pubitemid 24346245)
335. Kaufman, H. L., G. Deraffele, J. Mitcham, D. Moroziewicz, S. M. Cohen, K. S. Hurst-Wicker, K. Cheung, D. S. Lee, J. Divito, M. Voulo, J. Donovan, K. Dolan, K. Manson, D. Panicali, E. Wang, H. Horig & F. M. Marincola: Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest, 115, 1903-12 (2005) (Pubitemid 40979730)
336. Kudo-Saito, C., J. W. Hodge, H. Kwak, S. Kim-Schulze, J. Schlom & H. L. Kaufman: 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine, 24, 4975-86 (2006) (Pubitemid 43782689)
337. Vianello, F., N. Papeta, T. Chen, P. Kraft, N. White, W. K. Hart, M. F. Kircher, E. Swart, S. Rhee, G. Palu, D. Irimia, M. Toner, R. Weissleder & M. C. Poznansky: Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J Immunol, 176, 2902-14 (2006)
338. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, M. R. Robinson, M. Raffeld, P. Duray, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, S. A. Mavroukakis, D. E. White & S. A. Rosenberg: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 298, 850-4 (2002) (Pubitemid 35231542)
339. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, Z. Zheng, A. Nahvi, C. R. de Vries, L. J. Rogers-Freezer, S. A. Mavroukakis & S. A. Rosenberg: Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science (2006)
340. Shevach, E. M.: Fatal attraction: tumors beckon regulatory T cells. Nature Med., 10, 900-901 (2004) (Pubitemid 39273725)
341. Wei, W. Z., G. P. Morris & Y. C. Kong: Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother, 53, 73-8 (2004) (Pubitemid 38161212)
342. Turk, M. J., J. A. Guevara-Patino, G. A. Rizzuto, M. E. Engelhorn & A. N. Houghton: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med., 200, 771-782 (2004) (Pubitemid 39299463)
343. Nagai, H., T. Horikawa, I. Hara, A. Fukunaga, S. Oniki, M. Oka, C. Nishigori & M. Ichihashi: In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp Dermatol, 13, 613-20 (2004) (Pubitemid 39345270)
344. Uyttenhove, C.: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nature Med., 9, 1269-1274 (2003) (Pubitemid 37279849)
345. Muller, A. J., J. B. DuHadaway, P. S. Donover, E. Sutanto-Ward & G. C. Prendergast: Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med, 11, 312-9 (2005) (Pubitemid 40460560)
346. Webster, W. S., E. J. Small, B. I. Rini & E. D. Kwon: Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol, 23, 8262-9 (2005) (Pubitemid 46211564)